Endpointa | OR (95% CI) | p value | |
---|---|---|---|
Anticoagulants versus antiplatelet therapyb | |||
PROFUND Index (1-year mortality risk) (Referral category: low) | < 0.0001 | ||
Low-intermediate | 0.455 (0.221–0.938) | 0.033 | |
Intermediate-high | 0.144 (0.067–0.312) | < 0.0001 | |
High | 0.133 (0.056–0.316) | < 0.0001 | |
Type of NVAF (Referral category: paroxysmal) | < 0.0001 | ||
Persistent | 2.077 (0.796–5.422) | 0.135 | |
Permanent | 4.122 (2.281–7.450) | < 0.0001 | |
Congestive heart failure (yes vs. no) | 2.084 (1.173–3.703) | 0.012 | |
VKAs versus DOACsc | |||
Gender (male vs. female) | 0.677 (0.478–0.959) | 0.028 | |
Educational level (Referral category: did not complete compulsory education) | 0.004 | ||
Primary education | 0.959 (0.617–1.491) | 0.853 | |
Secondary education | 0.534 (0.297–0.961) | 0.036 | |
University or higher | 0.337 (0.159–0.715) | 0.023 | |
Institutionalization (yes vs. no) | 7.744 (1.816–33.027) | 0.006 | |
Time since diagnosis of NVAF | 1.045 (1.011–1.080) | 0.009 | |
Prior stroke/TIA (yes vs. no) | 0.591 (0.386–0.903) | 0.015 |